OXUR.BR Oxurion NV (EURONEXT) pre-market 02 Apr 2026: earnings due, catalyst ahead

We see one clear catalyst for OXUR.BR stock: Oxurion NV reports earnings after the close on 03 Apr 2026. The stock trades on EURONEXT in Europe at €0.0056, with volume 427331 today and a market cap of €392,551.00. Investors should watch study results and cash metrics. We use this pre-market earnings spotlight to connect the report to near-term price movement and liquidity signals ahead of the release.

Earnings catalyst: OXUR.BR stock and the 03 Apr 2026 report

Oxurion NV files results that could change sentiment for OXUR.BR stock on 03 Apr 2026. Clinical updates for THR-149 and THR-687 and revenue recognition for legacy product JETREA are the main drivers. A positive trial update could lift interest; weak cash metrics could increase selling pressure.

One data point to watch is cash per share and operating cash flow. The company shows cash per share €0.00 (very low) and operating cash flow per share -0.19, which connects directly to dilution risk and near-term funding needs.

What to watch in the results: OXUR.BR stock metrics

Key metrics that move the tape will be EPS, R&D spend, and guidance. The public dataset lists EPS 2.23 but PE is not disclosed, so analysts will parse underlying accounting details closely. We expect commentary on trial timelines and cash runway.

Trading context matters: today’s range is €0.00 – €0.01 with a 50-day average price €0.01 and 200-day average price €0.02. Volume today of 427,331 versus avg volume 351,029 signals above-average attention.

Valuation and financial ratios for OXUR.BR stock

Valuation is mixed and skewed by small capitalization. Market cap is €392,551.00 and enterprise value shows as €11,216,551.00, producing a high EV/EBITDA signal relative to peers. Price to sales is 196.28, reflecting minimal public revenue. One clear ratio is the current ratio 0.17, which highlights short-term liquidity stress.

Investors should note R&D intensity: research and development to revenue is 352.50%, a sign of high burn. These ratios frame why analysts treat OXUR.BR stock as high risk despite experimental-stage assets.

Technical and market setup: OXUR.BR stock trading data

On technicals the RSI is 48.72, indicating neutral momentum, while ADX at 41.82 implies a strong trend is present in recent sessions. Price averages show a downtrend: 50-day average €0.01 vs 200-day average €0.02.

Liquidity is thin by large-market standards. Shares outstanding are 70,098,394 and relative volume is 1.23, so big trades will move price. Sector context: Healthcare (Biotechnology) in Europe is modestly down year-to-date, which can amplify volatility for small caps.

Meyka AI rates OXUR.BR with a score out of 100 and forecast

Meyka AI rates OXUR.BR with a score out of 100: 72.94 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Meyka AI’s forecast model projects a 12-month base target €0.01, implying +78.57% from the current price €0.0056. A bullish scenario at €0.03 implies +435.71% and a bearish scenario at €0.002 implies -64.29%. Forecasts are model-based projections and not guarantees.

Risks and opportunities for OXUR.BR stock

The largest opportunity is clinical success for THR-149 or THR-687, which could reopen partnership talks and valuation re-rating. Positive trial signals are a typical catalyst for biotech microcaps and can rapidly improve liquidity.

The main risks are cash runway, potential dilution, and limited revenue. Working capital is negative and the current ratio is low, so poor trial news could trigger dilution or deeper share-price declines.

Final Thoughts

OXUR.BR stock sits at the intersection of clinical binary risk and thin-market dynamics ahead of the 03 Apr 2026 earnings release. Tradeable signals are clear: watch trial commentary, cash runway, and reported operating cash flow per share -0.19. Our technical read shows neutral RSI 48.72 with above-average volume 427,331, implying any news will have outsized price impact. Meyka AI’s forecast model projects a base 12-month target €0.01 versus the current price €0.0056, an implied upside of 78.57%, while a bearish case would be €0.002 (implied -64.29%). Use the earnings call as a short-term catalyst, and factor in funding and dilution risks before increasing exposure. For real-time updates, check the earnings calendar and comparative industry data on Investing.com and our platform at the Meyka stock page for OXUR.BR.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.